{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-084142","form_type":"8-K","ticker":"SEPN","cik":"0001984086","company_name":"Septerna, Inc.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.937188+00:00","generated_at":"2026-05-15T22:50:10.839887+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Septerna reports positive Phase 1 data for oral MRGPRX2 NAM SEP-631, plans Phase 2 in chronic spontaneous urticaria","bullets":["SEP-631 well-tolerated; adverse event profile comparable to placebo across all doses studied","Complete inhibition of icatibant-induced skin wheal formation at doses as low as 10 mg once daily","Pharmacokinetic profile supports once-daily dosing with approximately 24-hour half-life","Company plans Phase 2b trial in chronic spontaneous urticaria in the second half of 2026"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-084142","json":"https://secwatch.observer/filing/0001193125-26-084142.json","markdown":"https://secwatch.observer/filing/0001193125-26-084142.md","text":"https://secwatch.observer/filing/0001193125-26-084142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526084142/0001193125-26-084142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526084142/d44190d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T22:50:10.839887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}